Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment

• Published in: International journal of molecular sciences Vol. 23; no. 7; p. 3418
• Main Authors: Yanai, Hidekatsu, Adachi, Hiroki, Hakoshima, Mariko, Katsuyama, Hisayuki
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.03.2022; MDPI
• Subjects: ABC transporters; Abnormalities; Absorption; Acute coronary syndromes; Agonists; Arteriosclerosis; Atherosclerosis; Atherosclerosis - drug therapy; Body fat; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - drug therapy; Cholesterol; Cholesterol, HDL; Clinical trials; Cytokines; Diabetes mellitus; Disease prevention; ezetimibe; Ezetimibe - therapeutic use; High density lipoprotein; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Inflammation; Insulin; Insulin Resistance; Intestine; Lipids; Lipoproteins; Liver; Low density lipoprotein; Low density lipoprotein receptors; Metabolic syndrome; Mortality; Patients; peroxisome proliferator-activated receptor alpha; Placebos; PPAR alpha; Randomized Controlled Trials as Topic; Review; Risk; Small intestine; Statins; Sterols; Transportation systems; triglyceride; Triglycerides; Japan; triglyceride; cardiovascular diseases; ezetimibe; peroxisome proliferator-activated receptor alpha; statins
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23073418

Several randomized, double blind, placebo-controlled trials (RCTs) have demonstrated that low-density lipoprotein cholesterol (LDL-C) lowering by using statins, including high-doses of strong statins, reduced the development of cardiovascular disease (CVD). However, among the eight RCTs which investigated the effect of statins vs. placebos on the development of CVD, 56-79% of patients had the residual CVD risk after the trials. In three RCTs which investigated the effect of a high dose vs. a usual dose of statins on the development of CVD, 78-87% of patients in the high-dose statin arms still had the CVD residual risk after the trials. An analysis of the characteristics of patients in the RCTs suggests that elevated triglyceride (TG) and reduced high-density lipoprotein cholesterol (HDL-C), the existence of obesity/insulin resistance, and diabetes may be important metabolic factors which determine the statin residual CVD risk. To understand the association between lipid abnormalities and the development of atherosclerosis, we show the profile of lipoproteins and their normal metabolism, and the molecular and biological mechanisms for the development of atherosclerosis by high TG and/or low HDL-C in insulin resistance. The molecular biological mechanisms for the statin residual CVD risk include an increase of atherogenic lipoproteins such as small dense LDL and remnants, vascular injury and remodeling by inflammatory cytokines, and disturbed reverse cholesterol transport. Peroxisome proliferator-activated receptor alpha (PPARα) agonists improve atherogenic lipoproteins, reverse the cholesterol transport system, and also have vascular protective effects, such as an anti-inflammatory effect and the reduction of the oxidative state. Ezetimibe, an inhibitor of intestinal cholesterol absorption, also improves TG and HDL-C, and reduces intestinal cholesterol absorption and serum plant sterols, which are increased by statins and are atherogenic, possibly contributing to reduce the statin residual CVD risk.